| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Obesity | 31 | 2023 | 839 | 4.980 |
Why?
|
| Overweight | 18 | 2023 | 272 | 3.320 |
Why?
|
| Body Weight | 18 | 2023 | 216 | 3.150 |
Why?
|
| Body Mass Index | 34 | 2023 | 961 | 2.600 |
Why?
|
| Hypertension | 6 | 2023 | 489 | 2.480 |
Why?
|
| Child | 35 | 2024 | 2519 | 2.140 |
Why?
|
| Female | 109 | 2023 | 12838 | 1.990 |
Why?
|
| Humans | 127 | 2024 | 18058 | 1.980 |
Why?
|
| Adolescent | 43 | 2024 | 3714 | 1.920 |
Why?
|
| Male | 90 | 2024 | 10173 | 1.870 |
Why?
|
| Dietary Fiber | 9 | 2007 | 59 | 1.690 |
Why?
|
| Pediatric Obesity | 4 | 2024 | 75 | 1.570 |
Why?
|
| Hispanic Americans | 11 | 2014 | 431 | 1.480 |
Why?
|
| Leptin | 11 | 2018 | 30 | 1.400 |
Why?
|
| Adiponectin | 6 | 2008 | 22 | 1.370 |
Why?
|
| California | 24 | 2023 | 2327 | 1.250 |
Why?
|
| Insulin | 12 | 2008 | 208 | 1.220 |
Why?
|
| Prevalence | 19 | 2024 | 892 | 1.210 |
Why?
|
| Weight Gain | 6 | 2023 | 180 | 1.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 8 | 2020 | 742 | 1.170 |
Why?
|
| Young Adult | 25 | 2020 | 2479 | 1.140 |
Why?
|
| Child, Preschool | 17 | 2023 | 1428 | 1.140 |
Why?
|
| Peptide Hormones | 7 | 2007 | 8 | 1.120 |
Why?
|
| Risk Factors | 32 | 2023 | 3394 | 1.120 |
Why?
|
| Adult | 58 | 2023 | 7696 | 1.100 |
Why?
|
| Cross-Sectional Studies | 20 | 2020 | 1309 | 1.060 |
Why?
|
| Diet, Vegetarian | 6 | 2007 | 12 | 1.060 |
Why?
|
| Resistin | 6 | 2008 | 6 | 1.050 |
Why?
|
| Ethnic Groups | 8 | 2019 | 504 | 1.020 |
Why?
|
| Isoflavones | 5 | 2006 | 14 | 0.960 |
Why?
|
| Lipids | 6 | 2012 | 77 | 0.940 |
Why?
|
| Phenols | 4 | 2008 | 34 | 0.930 |
Why?
|
| Weight Loss | 10 | 2022 | 296 | 0.920 |
Why?
|
| Middle Aged | 56 | 2019 | 8073 | 0.910 |
Why?
|
| Galactans | 4 | 2007 | 4 | 0.900 |
Why?
|
| Mannans | 4 | 2007 | 4 | 0.900 |
Why?
|
| Streptococcal Infections | 1 | 2023 | 21 | 0.890 |
Why?
|
| Flavonoids | 3 | 2007 | 5 | 0.880 |
Why?
|
| Blood Glucose | 11 | 2013 | 344 | 0.870 |
Why?
|
| Weight Reduction Programs | 2 | 2022 | 55 | 0.870 |
Why?
|
| Continental Population Groups | 4 | 2013 | 317 | 0.850 |
Why?
|
| Homocysteine | 3 | 2006 | 12 | 0.820 |
Why?
|
| Body Height | 5 | 2020 | 59 | 0.820 |
Why?
|
| Cohort Studies | 20 | 2023 | 2631 | 0.810 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 138 | 0.790 |
Why?
|
| Psoriasis | 2 | 2011 | 9 | 0.780 |
Why?
|
| Pregnancy | 9 | 2023 | 1484 | 0.760 |
Why?
|
| Triglycerides | 10 | 2012 | 86 | 0.760 |
Why?
|
| Cardiovascular Diseases | 8 | 2017 | 613 | 0.740 |
Why?
|
| Ghrelin | 9 | 2008 | 15 | 0.720 |
Why?
|
| African Americans | 4 | 2014 | 485 | 0.720 |
Why?
|
| Motor Activity | 5 | 2009 | 208 | 0.720 |
Why?
|
| Asthma | 2 | 2013 | 302 | 0.710 |
Why?
|
| Plant Gums | 4 | 2007 | 4 | 0.690 |
Why?
|
| Socioeconomic Factors | 7 | 2017 | 667 | 0.690 |
Why?
|
| Metabolic Syndrome | 4 | 2014 | 80 | 0.680 |
Why?
|
| Cross-Over Studies | 13 | 2008 | 42 | 0.670 |
Why?
|
| Surveys and Questionnaires | 15 | 2017 | 1346 | 0.660 |
Why?
|
| Vitamin B 12 | 5 | 2006 | 15 | 0.650 |
Why?
|
| Electronic Health Records | 7 | 2019 | 734 | 0.650 |
Why?
|
| Xylans | 3 | 2006 | 3 | 0.640 |
Why?
|
| Plant Oils | 2 | 2008 | 4 | 0.620 |
Why?
|
| Insulin Resistance | 7 | 2018 | 129 | 0.610 |
Why?
|
| Diet | 9 | 2012 | 359 | 0.610 |
Why?
|
| Obesity, Morbid | 5 | 2024 | 121 | 0.590 |
Why?
|
| Cholesterol, LDL | 5 | 2020 | 124 | 0.590 |
Why?
|
| Managed Care Programs | 3 | 2013 | 356 | 0.580 |
Why?
|
| Postmenopause | 8 | 2020 | 266 | 0.580 |
Why?
|
| United States | 17 | 2024 | 4119 | 0.570 |
Why?
|
| Glucose Intolerance | 2 | 2006 | 45 | 0.560 |
Why?
|
| Arginine | 2 | 2006 | 12 | 0.550 |
Why?
|
| Contraceptives, Oral | 2 | 2013 | 25 | 0.540 |
Why?
|
| Retrospective Studies | 12 | 2024 | 2498 | 0.540 |
Why?
|
| Sex Factors | 9 | 2015 | 634 | 0.530 |
Why?
|
| Cholesterol | 6 | 2012 | 112 | 0.530 |
Why?
|
| Aged | 33 | 2019 | 6258 | 0.530 |
Why?
|
| Multiple Sclerosis | 2 | 2017 | 97 | 0.510 |
Why?
|
| Censuses | 2 | 2012 | 32 | 0.510 |
Why?
|
| Body Composition | 10 | 2007 | 80 | 0.510 |
Why?
|
| Bariatric Surgery | 4 | 2024 | 128 | 0.510 |
Why?
|
| Blood Pressure Determination | 1 | 2015 | 56 | 0.500 |
Why?
|
| Glucose | 4 | 2007 | 30 | 0.500 |
Why?
|
| Insulin-Secreting Cells | 2 | 2018 | 19 | 0.480 |
Why?
|
| Prehypertension | 1 | 2013 | 21 | 0.450 |
Why?
|
| Postprandial Period | 4 | 2006 | 6 | 0.450 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2013 | 19 | 0.450 |
Why?
|
| Demyelinating Diseases | 1 | 2013 | 3 | 0.450 |
Why?
|
| Gallstones | 1 | 2012 | 14 | 0.430 |
Why?
|
| Peptide YY | 3 | 2006 | 5 | 0.430 |
Why?
|
| Arm Injuries | 1 | 2012 | 4 | 0.430 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2020 | 125 | 0.430 |
Why?
|
| Leg Injuries | 1 | 2012 | 8 | 0.430 |
Why?
|
| Contraception | 1 | 2012 | 25 | 0.430 |
Why?
|
| Asian Americans | 3 | 2012 | 184 | 0.420 |
Why?
|
| Estrogen Receptor beta | 3 | 2006 | 12 | 0.420 |
Why?
|
| Health Surveys | 3 | 2017 | 266 | 0.420 |
Why?
|
| Musculoskeletal Pain | 1 | 2012 | 26 | 0.410 |
Why?
|
| Double-Blind Method | 10 | 2006 | 160 | 0.410 |
Why?
|
| Cholesterol, HDL | 4 | 2012 | 80 | 0.400 |
Why?
|
| Dyslipidemias | 1 | 2012 | 63 | 0.400 |
Why?
|
| European Continental Ancestry Group | 4 | 2012 | 559 | 0.390 |
Why?
|
| Mass Screening | 2 | 2015 | 678 | 0.390 |
Why?
|
| Probiotics | 3 | 2008 | 4 | 0.390 |
Why?
|
| Age Factors | 9 | 2015 | 945 | 0.390 |
Why?
|
| Birth Certificates | 1 | 2010 | 22 | 0.380 |
Why?
|
| Exercise | 6 | 2012 | 478 | 0.370 |
Why?
|
| Patient Selection | 1 | 2012 | 194 | 0.370 |
Why?
|
| Soy Foods | 3 | 2006 | 10 | 0.370 |
Why?
|
| Severity of Illness Index | 6 | 2013 | 454 | 0.370 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2010 | 92 | 0.370 |
Why?
|
| Vegetables | 4 | 2009 | 80 | 0.360 |
Why?
|
| Erythrocytes | 3 | 2005 | 7 | 0.360 |
Why?
|
| Gastroesophageal Reflux | 1 | 2010 | 79 | 0.360 |
Why?
|
| Fatty Liver | 1 | 2009 | 6 | 0.350 |
Why?
|
| Energy Metabolism | 3 | 2005 | 47 | 0.340 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2012 | 552 | 0.340 |
Why?
|
| Feeding Behavior | 5 | 2020 | 165 | 0.330 |
Why?
|
| Prospective Studies | 13 | 2012 | 1294 | 0.330 |
Why?
|
| Folic Acid | 3 | 2006 | 35 | 0.330 |
Why?
|
| Odds Ratio | 5 | 2017 | 692 | 0.330 |
Why?
|
| Adipokines | 2 | 2018 | 5 | 0.320 |
Why?
|
| Health | 1 | 2008 | 35 | 0.320 |
Why?
|
| Single-Blind Method | 7 | 2021 | 46 | 0.320 |
Why?
|
| Incidence | 8 | 2017 | 1297 | 0.310 |
Why?
|
| Energy Intake | 4 | 2009 | 100 | 0.310 |
Why?
|
| Pregnancy Complications | 2 | 2014 | 193 | 0.310 |
Why?
|
| Oxidative Stress | 2 | 2006 | 11 | 0.310 |
Why?
|
| Diagnostic Techniques, Endocrine | 1 | 2007 | 1 | 0.300 |
Why?
|
| Growth | 1 | 2007 | 1 | 0.300 |
Why?
|
| Hypercholesterolemia | 2 | 2004 | 33 | 0.300 |
Why?
|
| Lipid Metabolism | 4 | 2008 | 13 | 0.300 |
Why?
|
| Fasting | 2 | 2006 | 47 | 0.300 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2008 | 60 | 0.300 |
Why?
|
| Beverages | 2 | 2005 | 17 | 0.300 |
Why?
|
| DNA Damage | 1 | 2006 | 2 | 0.290 |
Why?
|
| Antidiarrheals | 1 | 2006 | 2 | 0.280 |
Why?
|
| Nitric Oxide | 1 | 2006 | 6 | 0.280 |
Why?
|
| Phytotherapy | 2 | 2005 | 13 | 0.280 |
Why?
|
| Nutrition Assessment | 2 | 2005 | 27 | 0.280 |
Why?
|
| Menopause | 2 | 2009 | 72 | 0.280 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2006 | 407 | 0.280 |
Why?
|
| Animals | 9 | 2021 | 250 | 0.280 |
Why?
|
| Soybean Proteins | 1 | 2006 | 4 | 0.270 |
Why?
|
| Hyperhomocysteinemia | 1 | 2005 | 5 | 0.270 |
Why?
|
| Primary Health Care | 3 | 2022 | 843 | 0.270 |
Why?
|
| Diet Records | 1 | 2005 | 32 | 0.270 |
Why?
|
| Infant | 5 | 2013 | 1212 | 0.260 |
Why?
|
| Deuterium Oxide | 1 | 2005 | 1 | 0.260 |
Why?
|
| Magnesium | 1 | 2005 | 6 | 0.260 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2005 | 9 | 0.250 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2004 | 3 | 0.250 |
Why?
|
| C-Reactive Protein | 4 | 2018 | 57 | 0.250 |
Why?
|
| Plants, Edible | 1 | 2004 | 6 | 0.250 |
Why?
|
| Documentation | 1 | 2005 | 45 | 0.250 |
Why?
|
| Diet, Fat-Restricted | 1 | 2004 | 36 | 0.250 |
Why?
|
| Waist Circumference | 3 | 2014 | 37 | 0.250 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 445 | 0.240 |
Why?
|
| Dietary Fats | 1 | 2004 | 90 | 0.240 |
Why?
|
| Attitude to Health | 1 | 2005 | 179 | 0.240 |
Why?
|
| Lactobacillus casei | 1 | 2003 | 1 | 0.240 |
Why?
|
| Constipation | 1 | 2003 | 4 | 0.240 |
Why?
|
| Wounds, Gunshot | 1 | 2023 | 14 | 0.230 |
Why?
|
| Hospitalization | 1 | 2009 | 813 | 0.230 |
Why?
|
| Neoplasms | 3 | 2017 | 464 | 0.230 |
Why?
|
| Streptococcus agalactiae | 1 | 2023 | 8 | 0.230 |
Why?
|
| beta Carotene | 3 | 2009 | 18 | 0.230 |
Why?
|
| Firearms | 1 | 2023 | 27 | 0.230 |
Why?
|
| Ideal Body Weight | 1 | 2023 | 10 | 0.220 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2023 | 13 | 0.220 |
Why?
|
| Polyphenols | 3 | 2007 | 3 | 0.220 |
Why?
|
| Communicable Disease Control | 1 | 2023 | 19 | 0.220 |
Why?
|
| Reproducibility of Results | 7 | 2013 | 394 | 0.220 |
Why?
|
| Fatty Acids, Nonesterified | 3 | 2007 | 12 | 0.220 |
Why?
|
| Transcobalamins | 1 | 2002 | 1 | 0.210 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2013 | 60 | 0.210 |
Why?
|
| Longitudinal Studies | 4 | 2018 | 705 | 0.210 |
Why?
|
| Anti-Asthmatic Agents | 2 | 2013 | 67 | 0.210 |
Why?
|
| Predictive Value of Tests | 4 | 2011 | 350 | 0.210 |
Why?
|
| Dominance, Cerebral | 1 | 2002 | 1 | 0.210 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2002 | 2 | 0.210 |
Why?
|
| Cerebral Cortex | 1 | 2002 | 2 | 0.210 |
Why?
|
| Autonomic Nervous System | 1 | 2002 | 3 | 0.210 |
Why?
|
| Epilepsy | 1 | 2002 | 13 | 0.210 |
Why?
|
| Infant, Newborn | 5 | 2014 | 852 | 0.210 |
Why?
|
| Comorbidity | 3 | 2013 | 618 | 0.200 |
Why?
|
| Germany | 7 | 2009 | 13 | 0.200 |
Why?
|
| Sleep Apnea, Obstructive | 4 | 2007 | 8 | 0.200 |
Why?
|
| Self Report | 2 | 2020 | 252 | 0.200 |
Why?
|
| Adipose Tissue | 3 | 2006 | 59 | 0.200 |
Why?
|
| Interleukin-6 | 3 | 2018 | 25 | 0.190 |
Why?
|
| Pediatrics | 2 | 2014 | 164 | 0.190 |
Why?
|
| Adiposity | 3 | 2018 | 66 | 0.190 |
Why?
|
| Pregnancy Outcome | 2 | 2014 | 158 | 0.190 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2020 | 5 | 0.180 |
Why?
|
| Pandemics | 1 | 2023 | 293 | 0.180 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 1 | 2020 | 4 | 0.180 |
Why?
|
| Health Behavior | 4 | 2012 | 379 | 0.180 |
Why?
|
| Food | 1 | 2020 | 30 | 0.180 |
Why?
|
| Dietary Sugars | 1 | 2020 | 6 | 0.180 |
Why?
|
| Caffeine | 1 | 2020 | 18 | 0.180 |
Why?
|
| Anti-Obesity Agents | 1 | 2019 | 18 | 0.180 |
Why?
|
| Smoking | 3 | 2013 | 465 | 0.170 |
Why?
|
| Phentermine | 1 | 2019 | 10 | 0.170 |
Why?
|
| Fruit | 3 | 2009 | 72 | 0.170 |
Why?
|
| Appetite Depressants | 1 | 2019 | 16 | 0.170 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2020 | 40 | 0.170 |
Why?
|
| Diet Fads | 1 | 1999 | 1 | 0.170 |
Why?
|
| Menstruation | 1 | 1999 | 8 | 0.170 |
Why?
|
| Life Style | 3 | 2012 | 329 | 0.170 |
Why?
|
| Anthropometry | 5 | 2014 | 63 | 0.170 |
Why?
|
| Treatment Outcome | 8 | 2021 | 1259 | 0.160 |
Why?
|
| Carotenoids | 3 | 2007 | 30 | 0.160 |
Why?
|
| Time Factors | 6 | 2017 | 1114 | 0.160 |
Why?
|
| Ovarian Neoplasms | 2 | 2009 | 48 | 0.160 |
Why?
|
| Reference Values | 2 | 2012 | 86 | 0.160 |
Why?
|
| Breast Neoplasms | 2 | 2020 | 1023 | 0.160 |
Why?
|
| Bifidobacterium | 2 | 2008 | 2 | 0.160 |
Why?
|
| Olive Oil | 2 | 2008 | 2 | 0.150 |
Why?
|
| Health Status Disparities | 1 | 2019 | 154 | 0.150 |
Why?
|
| Nutritional Status | 4 | 2009 | 30 | 0.150 |
Why?
|
| Acylation | 2 | 2007 | 2 | 0.150 |
Why?
|
| Dietary Supplements | 3 | 2008 | 91 | 0.150 |
Why?
|
| Insurance Claim Review | 2 | 2017 | 69 | 0.150 |
Why?
|
| Hypoglycemic Agents | 2 | 2013 | 289 | 0.150 |
Why?
|
| Glucose Tolerance Test | 4 | 2018 | 106 | 0.150 |
Why?
|
| Vitamin A | 3 | 2007 | 15 | 0.150 |
Why?
|
| Prognosis | 5 | 2020 | 619 | 0.150 |
Why?
|
| Solubility | 2 | 2007 | 4 | 0.150 |
Why?
|
| Satiety Response | 2 | 2006 | 2 | 0.150 |
Why?
|
| Exercise Tolerance | 1 | 2017 | 13 | 0.150 |
Why?
|
| Coronary Disease | 2 | 2012 | 182 | 0.140 |
Why?
|
| Meat | 2 | 2010 | 26 | 0.140 |
Why?
|
| Follow-Up Studies | 8 | 2016 | 1255 | 0.140 |
Why?
|
| Feces | 2 | 2008 | 84 | 0.140 |
Why?
|
| Adenocarcinoma | 3 | 2009 | 177 | 0.140 |
Why?
|
| Absorptiometry, Photon | 5 | 2014 | 59 | 0.140 |
Why?
|
| Europe | 2 | 2006 | 38 | 0.140 |
Why?
|
| Proportional Hazards Models | 5 | 2014 | 745 | 0.140 |
Why?
|
| Exercise Therapy | 1 | 2017 | 70 | 0.140 |
Why?
|
| Lipid Peroxidation | 2 | 2006 | 4 | 0.130 |
Why?
|
| Anticonvulsants | 2 | 2006 | 10 | 0.130 |
Why?
|
| Oxygen Isotopes | 2 | 2005 | 3 | 0.130 |
Why?
|
| Ambulatory Care | 2 | 2015 | 274 | 0.130 |
Why?
|
| Breast Feeding | 1 | 2017 | 134 | 0.130 |
Why?
|
| Biomarkers | 4 | 2009 | 306 | 0.130 |
Why?
|
| Logistic Models | 4 | 2013 | 953 | 0.130 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 526 | 0.120 |
Why?
|
| Case-Control Studies | 5 | 2017 | 1164 | 0.120 |
Why?
|
| African Continental Ancestry Group | 2 | 2012 | 165 | 0.120 |
Why?
|
| International Classification of Diseases | 2 | 2013 | 87 | 0.120 |
Why?
|
| Colitis, Ulcerative | 1 | 2014 | 10 | 0.120 |
Why?
|
| Crohn Disease | 1 | 2014 | 16 | 0.120 |
Why?
|
| Obesity, Abdominal | 1 | 2014 | 10 | 0.120 |
Why?
|
| Sex Distribution | 2 | 2012 | 192 | 0.120 |
Why?
|
| Gastrectomy | 1 | 2014 | 46 | 0.120 |
Why?
|
| Microsatellite Repeats | 2 | 2004 | 10 | 0.120 |
Why?
|
| Bronchodilator Agents | 1 | 2013 | 14 | 0.120 |
Why?
|
| Laparoscopy | 1 | 2014 | 48 | 0.120 |
Why?
|
| Lower Extremity | 1 | 2013 | 13 | 0.110 |
Why?
|
| Confidence Intervals | 2 | 2010 | 249 | 0.110 |
Why?
|
| Gastric Bypass | 1 | 2014 | 71 | 0.110 |
Why?
|
| Sex Characteristics | 3 | 2007 | 68 | 0.110 |
Why?
|
| Social Class | 1 | 2013 | 125 | 0.110 |
Why?
|
| Thinness | 1 | 2012 | 29 | 0.110 |
Why?
|
| Pseudotumor Cerebri | 1 | 2012 | 3 | 0.110 |
Why?
|
| Analysis of Variance | 3 | 2007 | 162 | 0.110 |
Why?
|
| Oxidation-Reduction | 3 | 2006 | 5 | 0.110 |
Why?
|
| Fractures, Bone | 1 | 2013 | 91 | 0.100 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2012 | 7 | 0.100 |
Why?
|
| Ovariectomy | 1 | 2011 | 9 | 0.100 |
Why?
|
| Faculty | 1 | 2011 | 5 | 0.100 |
Why?
|
| Oceanic Ancestry Group | 1 | 2012 | 34 | 0.100 |
Why?
|
| Pilot Projects | 2 | 2017 | 235 | 0.100 |
Why?
|
| Food, Fortified | 3 | 2006 | 5 | 0.100 |
Why?
|
| Family Characteristics | 1 | 2012 | 53 | 0.100 |
Why?
|
| Genotype | 3 | 2006 | 251 | 0.100 |
Why?
|
| Income | 1 | 2012 | 95 | 0.100 |
Why?
|
| Alanine Transaminase | 1 | 2011 | 22 | 0.100 |
Why?
|
| Educational Status | 1 | 2012 | 205 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 123 | 0.100 |
Why?
|
| Dermatology | 1 | 2011 | 6 | 0.100 |
Why?
|
| Arthritis, Psoriatic | 1 | 2011 | 5 | 0.100 |
Why?
|
| Phototherapy | 1 | 2011 | 22 | 0.100 |
Why?
|
| Adolescent Development | 1 | 2011 | 11 | 0.100 |
Why?
|
| Age of Onset | 1 | 2011 | 82 | 0.100 |
Why?
|
| Quality Control | 1 | 2010 | 45 | 0.100 |
Why?
|
| Health Planning | 1 | 2010 | 19 | 0.100 |
Why?
|
| Data Collection | 1 | 2012 | 276 | 0.090 |
Why?
|
| Colony Count, Microbial | 2 | 2007 | 3 | 0.090 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2007 | 15 | 0.090 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2010 | 1 | 0.090 |
Why?
|
| Carcinoma, Papillary | 1 | 2010 | 3 | 0.090 |
Why?
|
| Guideline Adherence | 1 | 2012 | 160 | 0.090 |
Why?
|
| Child Development | 1 | 2011 | 49 | 0.090 |
Why?
|
| Food Supply | 1 | 2010 | 35 | 0.090 |
Why?
|
| Poverty | 1 | 2012 | 177 | 0.090 |
Why?
|
| Catchment Area (Health) | 1 | 2010 | 8 | 0.090 |
Why?
|
| Prepaid Health Plans | 1 | 2010 | 22 | 0.090 |
Why?
|
| Thyroid Neoplasms | 1 | 2010 | 12 | 0.090 |
Why?
|
| Antioxidants | 2 | 2007 | 39 | 0.090 |
Why?
|
| Colon | 2 | 2007 | 21 | 0.090 |
Why?
|
| Health Services Research | 1 | 2012 | 271 | 0.090 |
Why?
|
| Public Health | 1 | 2010 | 80 | 0.090 |
Why?
|
| Bread | 2 | 2006 | 3 | 0.090 |
Why?
|
| Continuous Positive Airway Pressure | 3 | 2004 | 6 | 0.090 |
Why?
|
| Clostridium | 2 | 2006 | 3 | 0.090 |
Why?
|
| Enterobacteriaceae | 2 | 2006 | 3 | 0.090 |
Why?
|
| Glioma | 1 | 2009 | 5 | 0.090 |
Why?
|
| Area Under Curve | 2 | 2006 | 33 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 2009 | 15 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2007 | 129 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 324 | 0.090 |
Why?
|
| Residence Characteristics | 1 | 2012 | 248 | 0.090 |
Why?
|
| Linear Models | 2 | 2012 | 240 | 0.090 |
Why?
|
| Cesarean Section | 1 | 2009 | 29 | 0.090 |
Why?
|
| Hepatitis | 1 | 2009 | 5 | 0.090 |
Why?
|
| Stillbirth | 1 | 2009 | 30 | 0.090 |
Why?
|
| Chronic Disease | 2 | 2010 | 462 | 0.090 |
Why?
|
| Eating | 2 | 2006 | 37 | 0.090 |
Why?
|
| Liver Cirrhosis | 1 | 2009 | 34 | 0.080 |
Why?
|
| Body Constitution | 2 | 2006 | 36 | 0.080 |
Why?
|
| Gastric Emptying | 1 | 2008 | 1 | 0.080 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2008 | 1 | 0.080 |
Why?
|
| Carcinoma | 1 | 2009 | 27 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 1 | 2008 | 6 | 0.080 |
Why?
|
| Emergency Service, Hospital | 1 | 2012 | 357 | 0.080 |
Why?
|
| Pedigree | 1 | 2008 | 55 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2010 | 1137 | 0.080 |
Why?
|
| Family Health | 1 | 2008 | 47 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2010 | 205 | 0.080 |
Why?
|
| Stomach Neoplasms | 1 | 2008 | 42 | 0.080 |
Why?
|
| Inflammation | 2 | 2007 | 61 | 0.080 |
Why?
|
| Mexican Americans | 2 | 2018 | 48 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2005 | 318 | 0.080 |
Why?
|
| Health Status | 1 | 2010 | 331 | 0.080 |
Why?
|
| Centrifugation | 1 | 2007 | 1 | 0.080 |
Why?
|
| Esophageal Neoplasms | 1 | 2008 | 116 | 0.080 |
Why?
|
| Lipomatosis, Multiple Symmetrical | 1 | 2007 | 1 | 0.070 |
Why?
|
| Alcohol Drinking | 2 | 2008 | 375 | 0.070 |
Why?
|
| Anorexia | 1 | 2006 | 1 | 0.070 |
Why?
|
| Deoxyguanosine | 1 | 2006 | 1 | 0.070 |
Why?
|
| Somatostatin | 1 | 2006 | 1 | 0.070 |
Why?
|
| Food, Formulated | 1 | 2006 | 1 | 0.070 |
Why?
|
| RNA | 1 | 2006 | 12 | 0.070 |
Why?
|
| Hypothalamus | 1 | 2006 | 3 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2006 | 13 | 0.070 |
Why?
|
| Hominidae | 1 | 2006 | 1 | 0.070 |
Why?
|
| DNA | 1 | 2006 | 25 | 0.070 |
Why?
|
| Intestines | 1 | 2006 | 4 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2005 | 595 | 0.070 |
Why?
|
| Premenopause | 2 | 2020 | 27 | 0.070 |
Why?
|
| Calorimetry, Indirect | 1 | 2006 | 2 | 0.070 |
Why?
|
| Nitric Oxide Synthase | 1 | 2006 | 2 | 0.070 |
Why?
|
| Linkage Disequilibrium | 1 | 2006 | 38 | 0.070 |
Why?
|
| Estrogen Receptor alpha | 1 | 2006 | 27 | 0.070 |
Why?
|
| Epilepsies, Partial | 1 | 2006 | 1 | 0.070 |
Why?
|
| Piracetam | 1 | 2006 | 1 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 407 | 0.070 |
Why?
|
| Body Fat Distribution | 1 | 2006 | 5 | 0.070 |
Why?
|
| Taste | 1 | 2006 | 1 | 0.070 |
Why?
|
| Smell | 1 | 2006 | 2 | 0.070 |
Why?
|
| Minority Groups | 2 | 2019 | 103 | 0.070 |
Why?
|
| Genetic Variation | 1 | 2006 | 87 | 0.070 |
Why?
|
| Gastric Inhibitory Polypeptide | 1 | 2005 | 1 | 0.070 |
Why?
|
| Risk | 2 | 2017 | 552 | 0.070 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2005 | 4 | 0.070 |
Why?
|
| Deuterium | 1 | 2005 | 3 | 0.070 |
Why?
|
| Body Water | 1 | 2005 | 3 | 0.070 |
Why?
|
| Edible Grain | 1 | 2005 | 14 | 0.070 |
Why?
|
| Blood Proteins | 1 | 2005 | 3 | 0.070 |
Why?
|
| Proteomics | 1 | 2005 | 7 | 0.070 |
Why?
|
| Fructose | 1 | 2005 | 5 | 0.070 |
Why?
|
| Sweetening Agents | 1 | 2005 | 7 | 0.070 |
Why?
|
| Triazines | 1 | 2005 | 2 | 0.070 |
Why?
|
| Glycated Hemoglobin A | 1 | 2006 | 231 | 0.070 |
Why?
|
| Skinfold Thickness | 1 | 2005 | 18 | 0.060 |
Why?
|
| Bone and Bones | 1 | 2005 | 10 | 0.060 |
Why?
|
| Hemostatic Techniques | 1 | 2005 | 1 | 0.060 |
Why?
|
| Magnesium Deficiency | 1 | 2005 | 1 | 0.060 |
Why?
|
| Muscle Cramp | 1 | 2005 | 1 | 0.060 |
Why?
|
| Work | 1 | 2005 | 13 | 0.060 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2005 | 7 | 0.060 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2005 | 22 | 0.060 |
Why?
|
| Seizures | 1 | 2005 | 30 | 0.060 |
Why?
|
| Sports | 1 | 2005 | 21 | 0.060 |
Why?
|
| Lung Neoplasms | 1 | 2009 | 257 | 0.060 |
Why?
|
| Milk | 1 | 2004 | 8 | 0.060 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2005 | 105 | 0.060 |
Why?
|
| Eggs | 1 | 2004 | 9 | 0.060 |
Why?
|
| Leisure Activities | 1 | 2005 | 33 | 0.060 |
Why?
|
| Vitamins | 1 | 2005 | 66 | 0.060 |
Why?
|
| Placenta | 1 | 2005 | 19 | 0.060 |
Why?
|
| Education, Medical, Graduate | 1 | 2005 | 23 | 0.060 |
Why?
|
| Hormones, Ectopic | 1 | 2004 | 1 | 0.060 |
Why?
|
| Activities of Daily Living | 1 | 2005 | 92 | 0.060 |
Why?
|
| Computer Simulation | 1 | 2005 | 84 | 0.060 |
Why?
|
| Regression Analysis | 3 | 2014 | 319 | 0.060 |
Why?
|
| Clinical Competence | 1 | 2005 | 109 | 0.060 |
Why?
|
| Electric Impedance | 1 | 2004 | 6 | 0.060 |
Why?
|
| Intestinal Neoplasms | 1 | 2004 | 2 | 0.060 |
Why?
|
| Defecation | 1 | 2003 | 5 | 0.060 |
Why?
|
| Polysaccharides | 1 | 2003 | 3 | 0.060 |
Why?
|
| Immune System | 1 | 2003 | 2 | 0.060 |
Why?
|
| Epidemiologic Methods | 1 | 2004 | 86 | 0.060 |
Why?
|
| Semen | 1 | 2003 | 2 | 0.060 |
Why?
|
| Hypogonadism | 1 | 2003 | 4 | 0.060 |
Why?
|
| Poisson Distribution | 2 | 2014 | 92 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 30 | 0.060 |
Why?
|
| Age Distribution | 1 | 2023 | 257 | 0.060 |
Why?
|
| Autoantigens | 1 | 2002 | 2 | 0.060 |
Why?
|
| Pemphigoid, Bullous | 1 | 2002 | 2 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 1956 | 0.050 |
Why?
|
| Palliative Care | 1 | 2003 | 57 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2003 | 49 | 0.050 |
Why?
|
| Limbic System | 1 | 2002 | 1 | 0.050 |
Why?
|
| Piloerection | 1 | 2002 | 1 | 0.050 |
Why?
|
| Shivering | 1 | 2002 | 1 | 0.050 |
Why?
|
| Cats | 1 | 2021 | 7 | 0.050 |
Why?
|
| Fluoxetine | 1 | 2021 | 26 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2002 | 103 | 0.050 |
Why?
|
| Folic Acid Deficiency | 1 | 2001 | 3 | 0.050 |
Why?
|
| Psychotherapy | 1 | 2021 | 58 | 0.050 |
Why?
|
| Anxiety Disorders | 1 | 2021 | 91 | 0.050 |
Why?
|
| Poultry Products | 1 | 2020 | 1 | 0.050 |
Why?
|
| Nuts | 1 | 2020 | 3 | 0.050 |
Why?
|
| Food Analysis | 1 | 2020 | 4 | 0.050 |
Why?
|
| Chickens | 1 | 2020 | 6 | 0.050 |
Why?
|
| ROC Curve | 2 | 2013 | 79 | 0.050 |
Why?
|
| Mothers | 2 | 2014 | 110 | 0.040 |
Why?
|
| Diet Surveys | 1 | 2020 | 57 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2019 | 25 | 0.040 |
Why?
|
| Nutrition Surveys | 2 | 2010 | 65 | 0.040 |
Why?
|
| Amenorrhea | 1 | 1999 | 3 | 0.040 |
Why?
|
| Prediabetic State | 1 | 2019 | 50 | 0.040 |
Why?
|
| Reproductive Physiological Phenomena | 1 | 2017 | 3 | 0.040 |
Why?
|
| Infant, Premature | 2 | 2008 | 60 | 0.040 |
Why?
|
| Avena | 2 | 2006 | 2 | 0.040 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2007 | 8 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2003 | 643 | 0.030 |
Why?
|
| Base Sequence | 2 | 2006 | 20 | 0.030 |
Why?
|
| Immunoglobulin A | 2 | 2008 | 4 | 0.030 |
Why?
|
| Equol | 2 | 2006 | 2 | 0.030 |
Why?
|
| Phytoestrogens | 2 | 2006 | 7 | 0.030 |
Why?
|
| Hydrogen | 2 | 2006 | 3 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2007 | 9 | 0.030 |
Why?
|
| Electroencephalography | 2 | 2006 | 4 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2006 | 118 | 0.030 |
Why?
|
| Phenotype | 2 | 2007 | 145 | 0.030 |
Why?
|
| Mice | 2 | 2005 | 66 | 0.030 |
Why?
|
| Fetal Membranes, Premature Rupture | 1 | 2014 | 11 | 0.030 |
Why?
|
| Polysomnography | 2 | 2004 | 6 | 0.030 |
Why?
|
| Growth Charts | 1 | 2014 | 1 | 0.030 |
Why?
|
| Spain | 1 | 2014 | 5 | 0.030 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2014 | 56 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2004 | 44 | 0.030 |
Why?
|
| Immunoglobulin G | 2 | 2003 | 27 | 0.030 |
Why?
|
| Discriminant Analysis | 1 | 2012 | 5 | 0.030 |
Why?
|
| Demography | 1 | 2013 | 106 | 0.030 |
Why?
|
| Habits | 1 | 2012 | 7 | 0.030 |
Why?
|
| Physical Fitness | 1 | 2012 | 73 | 0.030 |
Why?
|
| Premature Birth | 1 | 2014 | 135 | 0.030 |
Why?
|
| Algorithms | 1 | 2013 | 235 | 0.030 |
Why?
|
| United States Department of Agriculture | 1 | 2010 | 1 | 0.020 |
Why?
|
| Meat Products | 1 | 2010 | 3 | 0.020 |
Why?
|
| Nutrition Policy | 1 | 2010 | 18 | 0.020 |
Why?
|
| Counseling | 1 | 2012 | 199 | 0.020 |
Why?
|
| Research Design | 1 | 2012 | 393 | 0.020 |
Why?
|
| Food Handling | 1 | 2009 | 6 | 0.020 |
Why?
|
| Nutritive Value | 1 | 2009 | 11 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2009 | 8 | 0.020 |
Why?
|
| Fetal Distress | 1 | 2009 | 4 | 0.020 |
Why?
|
| Chorioamnionitis | 1 | 2009 | 18 | 0.020 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2009 | 2 | 0.020 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2009 | 3 | 0.020 |
Why?
|
| Hormone Replacement Therapy | 1 | 2009 | 28 | 0.020 |
Why?
|
| Gastroparesis | 1 | 2008 | 1 | 0.020 |
Why?
|
| Gestational Age | 1 | 2009 | 119 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2009 | 24 | 0.020 |
Why?
|
| Acetates | 1 | 2008 | 1 | 0.020 |
Why?
|
| Leukocyte L1 Antigen Complex | 1 | 2008 | 1 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2008 | 3 | 0.020 |
Why?
|
| Endometrial Neoplasms | 1 | 2009 | 39 | 0.020 |
Why?
|
| Lactic Acid | 1 | 2008 | 9 | 0.020 |
Why?
|
| Confounding Factors (Epidemiology) | 1 | 2009 | 97 | 0.020 |
Why?
|
| Time | 1 | 2007 | 20 | 0.020 |
Why?
|
| DNA, Mitochondrial | 1 | 2007 | 3 | 0.020 |
Why?
|
| Nuclear Family | 1 | 2007 | 7 | 0.020 |
Why?
|
| Fathers | 1 | 2007 | 10 | 0.020 |
Why?
|
| Centers for Disease Control and Prevention (U.S.) | 1 | 2007 | 33 | 0.020 |
Why?
|
| Medical History Taking | 1 | 2007 | 35 | 0.020 |
Why?
|
| P-Selectin | 1 | 2007 | 1 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2006 | 5 | 0.020 |
Why?
|
| Receptors, Leptin | 1 | 2006 | 3 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2009 | 198 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2006 | 1 | 0.020 |
Why?
|
| Injections, Intraventricular | 1 | 2006 | 1 | 0.020 |
Why?
|
| Nitrobenzenes | 1 | 2006 | 1 | 0.020 |
Why?
|
| Triticum | 1 | 2006 | 1 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2006 | 3 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2006 | 2 | 0.020 |
Why?
|
| Hunger | 1 | 2006 | 4 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2006 | 6 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2006 | 3 | 0.020 |
Why?
|
| Amides | 1 | 2006 | 4 | 0.020 |
Why?
|
| Cell Count | 1 | 2006 | 10 | 0.020 |
Why?
|
| Rats | 1 | 2006 | 28 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2006 | 21 | 0.020 |
Why?
|
| Retinol-Binding Proteins, Plasma | 1 | 2006 | 1 | 0.020 |
Why?
|
| Retinol-Binding Proteins | 1 | 2006 | 2 | 0.020 |
Why?
|
| Species Specificity | 1 | 2006 | 5 | 0.020 |
Why?
|
| Zeaxanthins | 1 | 2006 | 6 | 0.020 |
Why?
|
| Xanthophylls | 1 | 2006 | 6 | 0.020 |
Why?
|
| Lutein | 1 | 2006 | 7 | 0.020 |
Why?
|
| Culture Media | 1 | 2006 | 2 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2006 | 28 | 0.020 |
Why?
|
| Health Promotion | 1 | 2009 | 295 | 0.020 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2006 | 13 | 0.020 |
Why?
|
| Mathematics | 1 | 2006 | 3 | 0.020 |
Why?
|
| Hyperinsulinism | 1 | 2006 | 9 | 0.020 |
Why?
|
| Breath Tests | 1 | 2006 | 7 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2006 | 18 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2007 | 51 | 0.020 |
Why?
|
| Videotape Recording | 1 | 2006 | 10 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 103 | 0.020 |
Why?
|
| RNA, Bacterial | 1 | 2006 | 1 | 0.020 |
Why?
|
| Oligonucleotide Probes | 1 | 2006 | 3 | 0.020 |
Why?
|
| Ecosystem | 1 | 2006 | 3 | 0.020 |
Why?
|
| Bacteroides | 1 | 2006 | 2 | 0.020 |
Why?
|
| Lipoprotein(a) | 1 | 2006 | 7 | 0.020 |
Why?
|
| Taste Threshold | 1 | 2006 | 1 | 0.020 |
Why?
|
| France | 1 | 2006 | 11 | 0.020 |
Why?
|
| Placebos | 1 | 2006 | 20 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2006 | 18 | 0.020 |
Why?
|
| Appetite Regulation | 1 | 2006 | 4 | 0.020 |
Why?
|
| Italy | 1 | 2006 | 15 | 0.020 |
Why?
|
| Sweden | 1 | 2006 | 18 | 0.020 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2006 | 6 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2006 | 30 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2006 | 57 | 0.020 |
Why?
|
| Registries | 1 | 2008 | 486 | 0.020 |
Why?
|
| Self Disclosure | 1 | 2006 | 24 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2006 | 39 | 0.020 |
Why?
|
| Starch | 1 | 2005 | 1 | 0.020 |
Why?
|
| Haptoglobins | 1 | 2005 | 1 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2005 | 1 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2005 | 5 | 0.020 |
Why?
|
| Random Allocation | 1 | 2005 | 42 | 0.020 |
Why?
|
| Peptides | 1 | 2005 | 12 | 0.020 |
Why?
|
| Liver | 1 | 2005 | 33 | 0.020 |
Why?
|
| Carbonated Beverages | 1 | 2005 | 14 | 0.020 |
Why?
|
| History, Ancient | 1 | 2005 | 2 | 0.020 |
Why?
|
| Carbamazepine | 1 | 2005 | 4 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2007 | 280 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2005 | 33 | 0.020 |
Why?
|
| Swine | 1 | 2005 | 3 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2005 | 37 | 0.020 |
Why?
|
| Oxidants | 1 | 2005 | 2 | 0.020 |
Why?
|
| Fellowships and Scholarships | 1 | 2005 | 14 | 0.020 |
Why?
|
| Estriol | 1 | 2005 | 2 | 0.020 |
Why?
|
| Lipoproteins, LDL | 1 | 2005 | 14 | 0.020 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2005 | 16 | 0.020 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2005 | 26 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2004 | 65 | 0.020 |
Why?
|
| Base Pair Mismatch | 1 | 2004 | 2 | 0.020 |
Why?
|
| DNA Repair | 1 | 2004 | 10 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2004 | 20 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2003 | 1 | 0.010 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2003 | 1 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2003 | 4 | 0.010 |
Why?
|
| Apolipoproteins | 1 | 2003 | 2 | 0.010 |
Why?
|
| Spleen | 1 | 2003 | 4 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2003 | 4 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2003 | 22 | 0.010 |
Why?
|
| Anticholesteremic Agents | 1 | 2003 | 14 | 0.010 |
Why?
|
| Oligospermia | 1 | 2003 | 1 | 0.010 |
Why?
|
| Plant Extracts | 1 | 2003 | 14 | 0.010 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2003 | 17 | 0.010 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2003 | 3 | 0.010 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2003 | 8 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 11 | 0.010 |
Why?
|
| Leucovorin | 1 | 2003 | 5 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2003 | 13 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 9 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2003 | 15 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2003 | 12 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2003 | 12 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2003 | 36 | 0.010 |
Why?
|
| Mucous Membrane | 1 | 2002 | 1 | 0.010 |
Why?
|
| Hemidesmosomes | 1 | 2002 | 1 | 0.010 |
Why?
|
| Non-Fibrillar Collagens | 1 | 2002 | 1 | 0.010 |
Why?
|
| Immunoglobulin E | 1 | 2002 | 2 | 0.010 |
Why?
|
| Epitopes | 1 | 2002 | 4 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2002 | 2 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 19 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 97 | 0.010 |
Why?
|
| Skin | 1 | 2002 | 14 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 2002 | 3 | 0.010 |
Why?
|
| Platelet Count | 1 | 2002 | 9 | 0.010 |
Why?
|
| APACHE | 1 | 2002 | 11 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2002 | 15 | 0.010 |
Why?
|
| Survival Rate | 1 | 2003 | 266 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2002 | 63 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2004 | 303 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2002 | 225 | 0.010 |
Why?
|